生物
病毒学
抗体
信使核糖核酸
中和抗体
病毒
Spike(软件开发)
穗蛋白
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019年冠状病毒病(COVID-19)
基因
免疫学
遗传学
医学
疾病
管理
病理
经济
传染病(医学专业)
作者
Magnus A. G. Hoffmann,Zhi Yang,Kathryn E. Huey‐Tubman,Alexander A. Cohen,Priyanthi N.P. Gnanapragasam,Leesa M. Nakatomi,Kaya N. Storm,Woohyun J. Moon,Paulo J.C. Lin,Anthony P. West,Pamela J. Björkman
出处
期刊:Cell
[Cell Press]
日期:2023-04-21
卷期号:186 (11): 2380-2391.e9
被引量:41
标识
DOI:10.1016/j.cell.2023.04.024
摘要
Prime-boost regimens for COVID-19 vaccines elicit poor antibody responses against Omicron-based variants and employ frequent boosters to maintain antibody levels. We present a natural infection-mimicking technology that combines features of mRNA- and protein nanoparticle-based vaccines through encoding self-assembling enveloped virus-like particles (eVLPs). eVLP assembly is achieved by inserting an ESCRT- and ALIX-binding region (EABR) into the SARS-CoV-2 spike cytoplasmic tail, which recruits ESCRT proteins to induce eVLP budding from cells. Purified spike-EABR eVLPs presented densely arrayed spikes and elicited potent antibody responses in mice. Two immunizations with mRNA-LNP encoding spike-EABR elicited potent CD8+ T cell responses and superior neutralizing antibody responses against original and variant SARS-CoV-2 compared with conventional spike-encoding mRNA-LNP and purified spike-EABR eVLPs, improving neutralizing titers >10-fold against Omicron-based variants for 3 months post-boost. Thus, EABR technology enhances potency and breadth of vaccine-induced responses through antigen presentation on cell surfaces and eVLPs, enabling longer-lasting protection against SARS-CoV-2 and other viruses.
科研通智能强力驱动
Strongly Powered by AbleSci AI